Development
Vera Therapeutics, Inc.
VERA
$19.25
-$1.39-6.73%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -39.90% | -90.35% | -126.86% | -173.10% | -25.29% |
| Total Depreciation and Amortization | -1,520.28% | -37,000.00% | -1,007.33% | -580.68% | 56.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.09% | 32.80% | 117.41% | 198.41% | 20.32% |
| Change in Net Operating Assets | 89.53% | 137.91% | -77.84% | 92.17% | 442.88% |
| Cash from Operations | -66.82% | -109.45% | -197.21% | -185.12% | -18.41% |
| Capital Expenditure | 100.00% | -58.33% | -144.44% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.90% | 26.98% | 57.65% | -1,309.80% | -- |
| Cash from Investing | 49.94% | 26.96% | 56.79% | -1,578.21% | -10,532.47% |
| Total Debt Issued | 302.68% | 302.68% | 302.68% | 302.68% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 33.65% | 35.95% | -15.00% | 70.54% | 68.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.63% | -19.05% | 14.54% | -120.51% | -94.02% |
| Cash from Financing | 50.24% | 52.55% | -3.38% | 89.18% | -33.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.03% | 59.20% | -58.23% | -239.45% | -165.58% |